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Summary
Background: Glucagon- like peptide- 1 receptor agonists may be a treatment option in 
patients with non- alcoholic fatty liver disease (NAFLD).
Aims: To investigate the effects of semaglutide on liver stiffness and liver fat in sub-
jects with NAFLD using non- invasive magnetic resonance imaging (MRI) methods.
Methods: This randomised, double- blind, placebo- controlled trial enrolled subjects 
with liver stiffness 2.50- 4.63 kPa by magnetic resonance elastography (MRE) and 
liver steatosis ≥10% by MRI proton density fat fraction (MRI- PDFF). The primary 
endpoint was change from baseline to week 48 in liver stiffness assessed by MRE.
Results: Sixty- seven subjects were randomised to once- daily subcutaneous semaglu-
tide 0.4 mg (n = 34) or placebo (n = 33). Change from baseline in liver stiffness was 
not significantly different between semaglutide and placebo at week 48 (estimated 
treatment ratio 0.96 (95% CI 0.89, 1.03; P = 0.2798); significant differences in liver 
stiffness were not observed at weeks 24 or 72. Reductions in liver steatosis were 
significantly greater with semaglutide (estimated treatment ratios: 0.70 [0.59, 0.84], 
P = 0.0002; 0.47 [0.36, 0.60], P < 0.0001; and 0.50 [0.39, 0.66], P < 0.0001) and 
more subjects achieved a ≥ 30% reduction in liver fat content with semaglutide at 
weeks 24, 48 and 72, (all P < 0.001). Decreases in liver enzymes, body weight and 
HbA1c were also observed with semaglutide.
Conclusions: The change in liver stiffness in subjects with NAFLD was not significantly 
different between semaglutide and placebo. However, semaglutide significantly re-
duced liver steatosis compared with placebo which, together with improvements in 
liver enzymes and metabolic parameters, suggests a positive impact on disease activ-
ity and metabolic profile.
ClinicalTrials.gov identifier: NCT03357380.
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1  | INTRODUC TION
NAFLD is a hepatic manifestation of the metabolic syndrome and is 
characterised by excessive hepatic fat accumulation associated with 
insulin resistance.1- 3 Liver biopsy remains the gold standard for the di-
agnosis and evaluation of treatment response, and is the only means 
to reliably differentiate non- alcoholic steatohepatitis (NASH) from 
NAFLD.2 However, the procedure is invasive with a risk of compli-
cations, such as bleeding, pain and infection. Biopsies can also be 
associated with high intra- and inter- observer variability, and the het-
erogeneity of liver structures and fibrosis, with samples only represent-
ing 1/50 000 of the liver can also be an issue.4,5 Imaging has emerged 
as an alternative to assess liver fat content and liver stiffness across 
the entire liver, with MRI- proton density fat fraction (MRI- PDFF) and 
MR elastography (MRE) regarded as the most accurate non- invasive 
methods to assess hepatic steatosis and fibrosis (liver stiffness), respec-
tively.4- 11 Both MRI- PDFF and MRE have also been used to evaluate 
treatment response in patients with NAFLD10,12- 14 and results correlate 
with biopsy findings.10 Lifestyle modification is currently the corner-
stone of treatment for patients with NAFLD, with weight loss being 
the primary focus.15 Currently available pharmacological options are 
limited15,16 but there are emerging data regarding the beneficial ef-
fects of glucagon- like peptide- 1 receptor agonists (GLP- 1RAs) among 
patients with NAFLD.15- 21 Subcutaneous semaglutide is a GLP- 1RA ap-
proved for the treatment of type 2 diabetes and obesity that has shown 
beneficial effects in reducing glycated haemoglobin (HbA1c) and body 
weight, as well as cardiovascular benefits in patients at high cardiovas-
cular risk.22- 26 In patients with NASH, treatment with semaglutide re-
sulted in a significantly higher percentage achieving NASH resolution 
with no worsening of fibrosis compared with placebo after 72 weeks of 
treatment in a phase 2 trial.21 The current trial investigated the effects 
of subcutaneous semaglutide on liver stiffness, a surrogate marker of 
fibrosis, and liver fat in subjects with NAFLD, using non- invasive MRI 
methods after 24, 48 and 72 weeks of treatment.
2  | MATERIAL S AND METHODS
2.1 | Trial design
This was a randomised, double- blind, placebo- controlled, parallel- 
group, two- centre, phase 1 clinical pharmacology trial, conducted 
over 72 weeks, that investigated the effects of subcutaneous sema-
glutide vs placebo in subjects with NAFLD and increased liver stiff-
ness (ClinicalTrials.gov identifier, NCT03357380).
The trial protocol was approved by relevant local independent 
ethics committees (Ärztekammer Nordrhein Ethikkommission, 
Düsseldorf and Ethik- Kommission der Landesärztekammer 
Rheinland- Pfalz, Mainz, both Germany) and was conducted in 
accordance with the Declaration of Helsinki and International 
Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use. All subjects provided written in-
formed consent before any trial- related activities were initiated.
2.2 | Subjects
Subjects aged 18- 75 years, with a BMI of 25- 40 kg/m2, liver stiff-
ness of 2.50- 4.63 kPa measured by MRE and >4.0 kPa measured 
via vibration controlled transient elastography (VCTE) (FibroScan®, 
EchoSens, Paris, France), in order to include a trial population with a 
high likelihood of histological fibrosis,9 liver steatosis ≥10 measured 
by MRI- PDFF, and with or without T2D were included in the trial.
Key exclusion criteria included: documented causes of chronic 
liver disease other than NAFLD (including NASH); positive test for 
hepatitis B surface antigens or hepatitis C antibodies, HIV- 1/HIV- 2 
antibodies or HIV- 1 antigen at screening; known or suspected in-
creased consumption of alcohol (>12 g/day for women; >24 g/day 
for men) or drugs; treatment with vitamin E or pioglitazone and 
HbA1c >9.5%. In addition, subjects with a diagnosis of type 1 diabe-
tes, those with a history or presence of pancreatitis (acute/chronic), 
and females who were pregnant or breastfeeding or of child- bearing 
potential and not using highly effective contraceptive methods were 
excluded. Other exclusion criteria included prior surgery for obe-
sity, current treatment with weight- loss therapies, and recent treat-
ment with other glucose- lowering medications, including GLP- 1RAs, 
sodium- glucose cotransporter- 2 inhibitors and insulin. Recent use of 
drugs with potential effects on steatosis, for example certain corti-
costeroids regimens, also led to exclusion.
2.3 | Trial treatments
Eligible subjects were randomised 1:1 to subcutaneous semaglu-
tide 0.4 mg once daily or placebo for 72 weeks. Randomisation was 
done using an IWRS and was stratified according to liver stiffness 
(<3.64– ≥3.64 kPa). A cut- off of 3.64 has been shown to have high 
diagnostic accuracy for discriminating advanced (stage 3- 4) from 
stage 0- 2 fibrosis.27 Semaglutide was initiated at 0.05 mg/day (or 
corresponding volume of placebo) for the first 4 weeks of treatment 
and thereafter increased every 4 weeks (0.1, 0.2 and 0.3 mg/day) to 
reach a target dose of 0.4 mg/day by week 16 (Figure S1). Injections 
were administered at approximately the same time of day. Subjects 
not reaching the target dose were permitted to stay on a lower dose 
and remain in the trial. Temporary cessation of the trial product for 
up to 21 days was permitted; however, after ≥21 days of treatment 
cessation, subjects were withdrawn from the trial. Nutritional and 
physical activity counselling were allowed during the trial but sub-
jects were not permitted to participate in any organised weight re-
duction programme.
2.4 | Endpoints
The primary endpoint was change from baseline to week 48 in liver 
stiffness assessed by MRE. Key secondary endpoints included: 
change from baseline to weeks 24 and 72 in liver stiffness assessed 
by MRE; the proportion of subjects achieving a ≥ 15% reduction in 
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liver stiffness (MRE) from baseline; liver steatosis evaluated by MRI- 
PDFF; and the proportion of subjects achieving a ≥ 30% reduction 
in liver fat content from baseline (MRI- PDFF). Other secondary end-
points were: change from baseline in total liver volume, liver fat vol-
ume, visceral adipose tissue and abdominal subcutaneous adipose 
tissue assessed by MRI; and changes from baseline in body weight, 
waist circumference and BMI.
Exploratory endpoints included: change from baseline in liver en-
zymes (alanine aminotransferase [ALT], aspartate aminotransferase 
[AST], gamma- glutamyl transferase [GGT]); glucose metabolism pa-
rameters (HbA1c, fasting plasma glucose, fasting glucagon, homeostatic 
model assessment of insulin resistance [HOMA- IR]) and cardiovascular 
risk factors (eg lipids, blood pressure and high- sensitivity C- reactive 
protein [hsCRP]). Exploratory blood biomarkers of liver fibrosis (serum 
enhanced liver fibrosis score, released N- terminal pro- peptide of type 
III collagen, neo- epitope in C- terminal of type VI collagen), apoptosis 
(cytokeratin 18 fragments), hepatotoxicity (microRNA 122), inflam-
mation (interleukin- 1 receptor antagonist [IL- 1RA], monocyte chemo-
attractant protein) and metabolism (FGF- 21, adiponectin) were also 
assessed, as were imaging biomarkers (liver stiffness measured by 
VCTE and steatosis assessed by controlled attenuation parameter). 
Changes in FibroScan- AST (FAST) score, which combines liver stiff-
ness measured by VCTE, steatosis by controlled attenuation parame-
ter and serum AST for the non- invasive identification of patients with 
NASH and ≥F2 fibrosis, were assessed post hoc.28
Vital signs (blood pressure, pulse), electrocardiogram and bio-
chemical and haematological parameters were measured during 
the trial. Adverse events (AEs; defined as events that had an onset 
date during the on- treatment period and coded using the Medical 
Dictionary for Regulatory Activities, version 22.1) and hypogly-
caemic episodes (classified according to the American Diabetes 
Association)29 were also reported.
2.5 | Magnetic resonance imaging and elastography 
assessments
MRE and MRI- PDFF assessments were performed at baseline and 
every 24 weeks after randomisation to evaluate liver stiffness and 
liver steatosis, respectively. MRI assessments were conducted as 
described previously.30 MRI/MRE assessments were conducted 
using a Siemens 1.5T MRI scanner. MRI- PDFF was performed using 
a 3D 6- echo gradient echo sequence covering the entire liver, and 
quantitative PDFF maps were reconstructed. MRI- PDFF was as-
sessed using regions of interest covering the entire liver, excluding 
bile ducts and veins. A separate T1- weighted scan was used to as-
sess liver volume. MRE scans were obtained in four axial slices, and 
in accordance with the Quantitative Imaging Biomarkers Alliance 
guidelines.31 In brief, the passive driver was placed over the right 
lower chest wall at the level of the xiphisternum in the midclav-
icular line. Regions of interest were drawn at least 1 cm inside the 
liver boundary, avoiding areas of incoherent waves, and contained 
a minimum of 500 pixels per slice.
Liver volume was determined by manual segmentation from 3D 
T1- weighted MR images. Liver fat volume was calculated by multi-
plying the liver volume by the liver fat fraction measured with the 
MRI- PDFF scan. The determination of visceral and abdominal subcu-
taneous adipose tissue volumes was undertaken using an automated 
algorithm for segmentation of visceral and abdominal subcutaneous 
adipose tissue from axial abdominal MRI data, which excluded inter-
muscular adipose tissue and bone marrow components. All MRI scans 
were performed following at least 4 hours of fasting.
2.6 | Statistical analysis
The sample size was calculated to detect a 15% reduction in the 
treatment ratio of MRE between semaglutide and placebo at the 5% 
significance level. Assuming a treatment ratio of 0.85 and a coef-
ficient of variation of 0.18, 54 subjects were required to complete 
48 weeks of treatment (and MR assessments) for 90% power; with 
an assumed dropout rate of 18%, a total sample size of 66 subjects 
was needed.
Analysis of efficacy was based on the full analysis set, which 
included all randomised subjects (as randomised population); the 
safety analysis set was used for safety endpoints, which included 
all subjects receiving at least one dose of randomised treatment (as 
treated population). Statistical analyses (efficacy and safety) were 
based on the treatment period starting on the date of first adminis-
tration of trial product and ending on the end- of- trial date.
The primary endpoint was analysed using mixed model for re-
peated measures with the log- transformed value of liver stiffness 
(MRE) as the response, and treatment, baseline categorical liver 
stiffness (MRE ≥3.64 kPa, <3.64 kPa) as factors, and baseline body 
weight and the log- transformed baseline liver stiffness as covariates, 
nested within weeks using an unstructured covariance matrix. From 
this model, the treatment ratio at week 48 was estimated for sema-
glutide vs placebo and the corresponding 95% confidence interval 
(CI) and the two- sided P value were calculated, together with the 
estimated ratio to baseline for each treatment arm. Potential missing 
data at week 48 were assumed to be missing at random.
The same mixed model for repeated measures used for the primary 
analysis estimation was also performed for all secondary endpoints, 
comparing treatment groups after 24, 48 and 72 weeks of treatment. 
Exploratory endpoints, including liver enzymes, glucose metabolism 
parameters, cardiovascular factors and biomarkers, were summarised. 
There was no prespecified strategy adjusting for multiple testing.
3  | RESULTS
3.1 | Subject disposition and baseline demographics 
and characteristics
Of 266 subjects screened for inclusion in the trial, 67 were 
enrolled, 34 of whom were randomised to semaglutide 0.4 mg 
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once daily and 33 to placebo (Figure S2). Of these, 27 subjects 
(79.4%) receiving semaglutide and 30 subjects (90.9%) receiving 
placebo completed the trial and had evaluable 48- week MRE 
data. Seven subjects in the semaglutide arm (including one sub-
ject not exposed to treatment) and three in the placebo group 
were withdrawn from the trial. The most common reason for 
withdrawal was withdrawal of consent (n = 5 semaglutide; n = 3 
placebo).
Baseline demographics and characteristics were gener-
ally well balanced with no major differences between the two 
groups (Table 1 and Table S1). The mean age was 60 years, and 
the majority of subjects were male (70%), had T2D (73%), and 
were classified as obese (BMI ≥30 kg/m2; 94%). Most subjects 
(85%) were in the low liver stiffness strata (only 10 subjects had a 
liver stiffness ≥3.64 kPa). The geometric means for liver stiffness 
(MRE) and liver steatosis (MRI- PDFF) were 3.02 kPa and 17.7%, 
respectively.
3.2 | Magnetic resonance imaging
3.2.1 | Change in liver stiffness
The primary endpoint of change from baseline in liver stiffness as 
assessed by MRE was not significantly different between semaglu-
tide and placebo at week 48 (Figure 1A). The estimated mean ratio 
to baseline at week 48 was 0.94 for semaglutide and 0.98 for pla-
cebo (P = .2798). No significant differences in liver stiffness were 
observed between semaglutide and placebo at week 24 (or week 
72). Individual changes in liver stiffness are shown in Figure S3A.
3.2.2 | Liver stiffness responders
No difference between semaglutide and placebo was seen in the 
proportion of subjects who achieved a ≥ 15% reduction in liver 
Semaglutide 
0.4 mg (n = 34)
Placebo 
(n = 33) Total (n = 67)
Age (years), mean (SD) 59.5 (10.1) 60.5 (8.5) 60.0 (9.3)
Male/female, n (%) 23 (67.6) / 11 
(32.4)




Caucasian, n (%) 34 (100) 33 (100) 67 (100)
Non- Hispanic/Non- Latino 34 (100) 33 (100) 67 (100)
HbA1c (%), mean (SD)
Type 2 diabetes 7.3 (0.9) 7.4 (1.0) 7.3 (1.0)
Non- type 2 diabetes 6.0 (0.5) 5.9 (0.3) 5.9 (0.4)
Body weight (kg), mean (SD) 105.1 (15.3) 102.3 (12.7) 103.7 (14.0)
Body mass index (kg/m2), n (%)
≥25- <30 2 (5.9) 2 (6.1) 4 (6.0)
≥30- <35 15 (44.1) 21 (63.6) 36 (53.7)
≥35 17 (50.0) 10 (30.3) 27 (40.3)
Liver stiffness strata by MRE, n (%)
Low (<3.64 kPa) 28 (82.4) 29 (87.9) 57 (85.1)
High (≥3.64 kPa) 6 (17.6) 4 (12.1) 10 (14.9)
MR scan, geometric mean (CV)
Liver stiffness by MRE (kPa) 3.08 (39.6) 2.95 (38.7) 3.02 (39.3)
Liver steatosis by MRI- PDFF (%) 18.1 (70.3) 17.3 (67.8) 17.7 (68.9)
Liver stiffness (kPa) by VCTE, geometric 
mean (CV)
8.9 (70.8) 8.1 (80.1) 8.5 (75.5)
Liver steatosis (dB/m) by controlled 
attenuation parameter, mean (SD)
350 (31) 332 (42) 341 (38)
Liver enzymes, geometric mean (CV)
Alanine aminotransferase (U/L) 40 (89.2) 35 (78.1) 37 (84.1)
Aspartate aminotransferase (U/L) 31 (71.5) 29 (62.8) 30 (67.6)
Abbreviation: CV, coefficient of variation; HbA1c, glycated haemoglobin; MRE, magnetic resonance 
elastography; MRI- PDFF, magnetic resonance imaging- proton density fat fraction; SD, standard 
deviation; VCTE, vibration controlled transient elastography.
TA B L E  1   Baseline demographics and 
clinical characteristics
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stiffness at weeks 24, 48 and 72, as assessed by MRE (Figure 1B). 
Fewer subjects treated with semaglutide had a ≥ 15% increase 
in liver stiffness (MRE) compared with placebo at week 48 (0 vs 
4 [13.3%] patients) and week 72 (1 [3.7%] vs 8 [27.6%] patients).
3.2.3 | Change in liver steatosis
As assessed by MRI- PDFF, liver fat content was reduced from 
baseline with semaglutide over the course of the trial (Figure 1C). 
The estimated mean ratio to baseline values for semaglutide vs 
placebo were significant at each timepoint (week 24: 0.64 vs 0.91 
[P = .0002]; week 48: 0.42 vs 0.89 [P < .0001]; week 72: 0.42 vs 
0.83 [P < .0001]). Individual changes in liver steatosis are shown in 
Figure S3B.
3.2.4 | Liver steatosis responders
At all timepoints, a significantly greater proportion of subjects 
achieved a ≥ 30% reduction in liver fat content, as assessed 
by MRI- PDFF, with semaglutide (P < .001 for each timepoint) 
(Figure 1D).
3.2.5 | Changes in other liver assessments by MRI
Significant differences between semaglutide and placebo were 
seen at all timepoints assessed in changes from baseline (measured 
as ratio to baseline) in liver fat volume (0.33- 0.52 vs 0.80- 0.88), 
total liver volume (0.79- 0.82 vs 0.96- 0.97), visceral adipose tissue 
(0.75- 0.83 vs 1.00- 1.03) and abdominal subcutaneous adipose 
F I G U R E  1   Changes from baseline in (A) liver stiffness by magnetic resonance elastography (MRE),* (B) proportion of subjects with 
a ≥ 15% reduction in liver stiffness by MRE,† (C) liver steatosis by magnetic resonance imaging- proton density fat fraction (MRI- PDFF) and 
(D) proportion of subjects with a ≥ 30% reduction in liver steatosis by MRI- PDFF† at weeks 24, 48 and 72 with semaglutide 0.4 mg once 
daily and placebo. *Change from baseline to week 48 represents the primary endpoint. †Proportions of subjects are based on observed 
data with missing data imputed by mixed model for repeated measures predicted values. Two- sided P value from logistic regression. 
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tissue (0.81- 0.87 vs 0.97- 1.00), assessed by MRI (all P < .0001 in 
favour of semaglutide at weeks 24, 48 and 72) (Figure 2).
3.3 | Vibration controlled transient elastography
Changes in liver stiffness assessed by VCTE were consistent with 
MRE assessments, with liver stiffness appearing to decrease with 
semaglutide and placebo at weeks 24 and 48, with no significant 
differences between treatments (Figure S3A). Also consistent with 
MRI- PDFF, decreases in liver steatosis assessed by controlled atten-
uation parameter were significant in favour of semaglutide at weeks 
48 and 72 (both P < .05) (Figure S3B).
3.4 | Metabolic parameters
Semaglutide was associated with significant reductions in body 
weight from baseline compared with placebo at all timepoints, 
with an estimated treatment difference (ETD) of – 9.68% (95% CI 
– 12.58, – 6.77; P < .0001) at week 72 (Table 2). Changes in BMI 
and waist circumference were consistent with body weight loss 
(data not shown). Furthermore, at week 72, there was a positive 
correlation between change in body weight and change in liver 
fat content by MRI- PDFF in both the placebo and semaglutide 
groups, with a large overlap in subjects achieving weight loss and 
a decrease in liver fat content, and in subjects with weight gain 
and an increase in liver fat content within each treatment group 
(Figure S4A).
In subjects with T2D, mean reductions from baseline in HbA1c 
were significantly greater for those treated with semaglutide com-
pared with placebo (P < .0001 at weeks 24, 48 and 72; Table 2). There 
was no correlation between change in HbA1c and change in liver fat 
by MRI- PDFF at week 72 in subjects with T2D; numbers of evaluable 
subjects without T2D were too low for any meaningful interpretation 
(Figure S4B). Changes from baseline to weeks 24, 48 and 72 in fasting 
plasma glucose in subjects with T2D were also significantly greater 
with semaglutide vs placebo (P < .05), while changes from baseline 
to weeks 24, 48 and 72 for HOMA- IR were not significantly different 
between semaglutide and placebo (Table 2). Changes in metabolic pa-
rameters for subjects without T2D are presented in Table S2.
3.5 | Liver enzymes, blood pressure and 
exploratory biomarkers
An 18- 28% reduction in liver enzymes (ALT, AST and GGT) was 
seen with semaglutide compared with placebo at weeks 48 and 
72 (P < .05; Figure 3A). There was a positive correlation between 
change in ALT and change in liver fat content by MRI- PDFF in both 
placebo and semaglutide groups at week 72, although no correlation 
was observed with AST (Figure S4C,D).
Mean change from baseline in systolic blood pressure was sig-
nificantly in favour of semaglutide vs placebo at weeks 24, 48 and 
F I G U R E  2   Changes from baseline (estimated treatment ratios and 95% confidence intervals) in total liver volume, liver fat volume, 
abdominal subcutaneous (s.c.) adipose tissue and visceral adipose tissue assessed by magnetic resonance imaging at weeks 24, 48 and 72 
with semaglutide 0.4 mg once daily and placebo. Data from on- treatment period. Estimates are from mixed model for repeated measures. 
EOT, end of treatment; SD, standard deviation
Baseline mean ± SD (L) Estimated treatment ratio
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72. For diastolic blood pressure, ETDs between semaglutide and 
placebo were significant at weeks 24 and 48, but not at week 72 
(Table S3).
Changes from baseline in exploratory biomarkers were vari-
able; significant differences between treatments were observed 
at weeks 48 and 72 for IL- 1RA and FGF- 21 (Figure 3B). Serum en-
hanced liver fibrosis score decreased with semaglutide at week 24 
and was significantly different compared with placebo: estimated 
mean change from baseline of – 0.19 and 0.26, respectively (ETD 
[95% CI] – 0.44 [– 0.70, – 0.19]; P = .0010) (Figure S5). No signifi-
cant differences between semaglutide and placebo were observed 
at weeks 48 and 72. Reductions in FAST score were greater with 
semaglutide than placebo and this difference was significant at 
week 48 (Table S4).
Decreases in hsCRP were observed with estimated treatment 
ratios (ETRs) (95% CI) significantly in favour of semaglutide vs 
placebo at weeks 48 (0.54 [0.38, 0.78]; P = .0015) and 72 (0.59 
[0.37, 0.92]; P = .0204). Triglycerides were also reduced at weeks 
48 (ETR 0.79 [0.68, 0.93]; P = .0039) and 72 (ETR 0.77 [0.65, 0.92]; 
P = .0043), but there were no apparent effects on other lipids 
(Figure S6).
3.6 | Safety and tolerability
The proportions of patients reporting overall AEs were similar in 
the semaglutide and placebo groups (93.9% vs 87.9%) (Table 3). 
Gastrointestinal AEs typically associated with GLP- 1RAs were re-
ported by more patients in the semaglutide than placebo group, with 
diarrhoea (30.3% vs 24.2%) and nausea (30.3% vs 9.1%) the most fre-
quent. Decreased appetite was also more frequent with semaglutide 
(42.4% vs 9.1%). Serious AEs were reported by 12.1% of patients in 
the semaglutide group (n = 4) and 9.1% in the placebo group (n = 3). 
No deaths occurred during the trial. In subjects with T2D, hypogly-
caemic episodes occurred in 4 (14.8%) patients treated with sema-
glutide and 2 (9.5%) patients in the placebo group.
4  | DISCUSSION
In this randomised, placebo- controlled trial in subjects with NAFLD, 
we found no significant difference between semaglutide and pla-
cebo in respect of the primary endpoint of decreased liver stiffness 
Semaglutide 
0.4 mg (n = 34)
Placebo 
(n = 33) P value
Mean relative change from baseline in body weight (%)
ETD (95% CI)
Week 24 – 8.34 – 0.25 – 8.09 (– 9.99, – 6.20) ≤ 0.0001
Week 48 – 11.18 – 0.65 – 10.52 (– 13.40, – 7.65) ≤ 0.0001
Week 72 – 10.83 – 1.15 – 9.68 (– 12.58, – 6.77) ≤ 0.0001
Mean change from baseline in HbA1c (%- points) – in subjects with T2D
n = 28 n = 21 ETD (95% CI)
Week 24 – 1.03 0.05 – 1.08 (– 1.44, – 0.72) ≤ 0.0001
Week 48 – 1.01 – 0.05 – 0.97 (– 1.34, – 0.60) ≤ 0.0001
Week 72 – 1.03 – 0.03 – 1.00 (– 1.38, – 0.62) ≤ 0.0001
Mean change from baseline in fasting plasma glucose (mmol/L) – in subjects with T2D
n = 27 n = 21 ETD (95% CI)
Week 24 – 1.97 0.04 – 2.01 (– 3.03, – 0.99) 0.0003
Week 48 – 1.34 0.04 – 1.38 (– 2.57, – 0.19) 0.0242
Week 72 – 1.74 – 0.28 – 1.47 (– 2.70, – 0.24) 0.0208
Mean ratio to baseline in fasting glucagon – in subjects with T2D
ETR (95% CI)
Week 24 0.69 1.00 0.69 (0.51, 0.92) 0.0124
Week 48 0.78 1.07 0.73 (0.55, 0.97) 0.0291
Week 72 0.63 0.91 0.69 (0.51, 0.93) 0.0169
Mean ratio to baseline in HOMA- IR – in subjects with T2D
ETR (95% CI)
Week 24 0.91 0.92 0.99 (0.70, 1.39) 0.9470
Week 48 0.87 0.89 0.98 (0.67, 1.43) 0.9065
Week 72 0.84 0.89 0.94 (0.60, 1.48) 0.7966
Abbreviations: CI, confidence interval; ETD, estimated treatment difference; ETR, estimated 
treatment ratio; HbA1c, glycated haemoglobin; HOMA- IR, Homeostatic Model Assessment of 
Insulin Resistance; T2D, type 2 diabetes.
TA B L E  2   Changes from baseline in 
metabolic parameters
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assessed by MRE. However, substantial and significant reductions in 
favour of semaglutide were recorded for liver steatosis at all time-
points using MRI- PDFF, with an ETR of 0.50 at week 72. Moreover, 
a ≥ 30% reduction in liver fat content, which is generally considered 
to be an MRI- PDFF response that is associated with histological re-
sponse and NASH resolution,13,14 was achieved by significantly more 
patients receiving semaglutide compared with placebo, with around 
three- quarters of subjects in the semaglutide group having a ≥ 30% 
relative decline in liver fat at weeks 48 and 72. Significant differ-
ences in favour of semaglutide at all timepoints were also observed 
for additional MRI assessments, including liver fat volume, total liver 
volume and abdominal subcutaneous and visceral adipose tissue, 
with ETRs in the range of 0.41- 0.86 at week 72.
Although more subjects receiving semaglutide compared with 
placebo achieved a ≥ 15% reduction in liver stiffness assessed by 
MRE, this difference was not significant. One possible reason why 
a significant difference was not observed is that MRE is not suffi-
ciently sensitive to detect changes in fibrosis in patients with less 
advanced disease.10,27 A limitation of our trial is that few subjects 
(15% overall) had advanced disease/a high degree of liver stiffness 
(≥3.64 kPa) at baseline, which may have made it difficult to detect 
a decrease in liver stiffness. The average MRE of 2.95- 3.08 kPa for 
the trial population at baseline corresponds to a borderline histo-
logical fibrosis of stage 1- 2, while the baseline PDFF values corre-
spond to grade 2- 3 steatosis.32 Another possible reason for the lack 
of significant reduction in liver stiffness in our trial is the timepoint 
of 48 weeks. Although 48 weeks was sufficient to show NASH reso-
lution with liraglutide in a previous study,18 in a recent study21 sema-
glutide showed no improvement in liver stiffness after 72 weeks; 
this may indicate that a much longer timeframe is required to detect 
an improvement in liver stiffness. Consistent with the liver stiffness 
findings recorded via MRE, VCTE assessment showed no significant 
differences between semaglutide and placebo.
Given that hepatic lipotoxicity is a prominent driving force of 
fibrosis progression and that steatosis and NASH are both revers-
ible conditions,29,33 our results showing that semaglutide reduces 
fat content in hepatocytes suggest the potential to reverse steatosis 
and halt fibrosis progression. Indeed, fewer subjects treated with 
semaglutide had a ≥ 15% increase in liver stiffness (MRE) compared 
with placebo at weeks 48 and 72. A 15% increase in liver stiffness 
assessed by MRE may be associated with fibrosis progression, in-
cluding transition from early to advanced fibrosis.34
F I G U R E  3   Changes from baseline (estimated treatment ratios and 95% confidence intervals) in (A) liver enzymes and (B) exploratory 
biomarkers at weeks 24, 48 and 72 with semaglutide 0.4 mg once daily and placebo. ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; CK- 18, cytokeratin 18 fragments; EOT, end of treatment; FGF- 21, fibroblast growth factor 21; GGT, gamma- glutamyl 
transferase, IL- 1RA, interleukin- 1 receptor antagonist; MCP1, monocyte chemoattractant protein- 1; mRNA, messenger RNA; Pro- C3, 
released N- terminal pro- peptide of type III collagen; Pro- C6, neo- epitope in C- terminal of type VI collagen; SD, standard deviation
Semaglutide 0.4 mg 
(n = 33) n (%)
Placebo 
(n = 33) n (%)
All adverse events 31 (93.9) 29 (87.9)
Serious adverse events 4 (12.1) 3 (9.1)
Fatal events 0 0
Adverse events leading to premature trial 
product discontinuation
1 (3.0) 0
Most frequent adverse events occurring in 
≥10% patients
Decreased appetite 14 (42.4) 3 (9.1)
Diarrhoea 10 (30.3) 8 (24.2)
Nausea 10 (30.3) 3 (9.1)
Vomiting 9 (27.3) 0
Nasopharyngitis 8 (24.2) 10 (30.3)
Constipation 8 (24.2) 2 (6.1)
Abdominal pain upper 6 (18.2) 2 (6.1)
Dizziness 6 (18.2) 2 (6.1)
Flatulence 6 (18.2) 2 (6.1)
Eructation 5 (15.2) 0
Headache 4 (12.1) 5 (15.2)
Fatigue 4 (12.1) 3 (9.1)
Early satiety 4 (12.1) 0
Note: n, number of subjects with event(s); %, proportion of subjects with event(s).
TA B L E  3   Adverse events overview 
(on- treatment)
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A significant difference in liver steatosis was demonstrated with 
semaglutide vs placebo, despite a high placebo response (73.5% of 
subjects in the semaglutide group vs 33.3% in the placebo group 
achieved a ≥ 30% reduction in liver steatosis). The reason for the 
high placebo response remains unknown; however, this has also 
been observed in other studies, including the recent 72- week phase 
2 trial of semaglutide in which 17% of placebo patients had resolu-
tion of NASH without fibrosis worsening as assessed by histology.21 
Furthermore, significant biochemical, histological and radiologi-
cal responses were observed in patients given placebo in a meta- 
analysis of randomised, controlled trials of pharmacotherapies for 
NASH.35
The effects of semaglutide with respect to steatosis and liver 
fat volume were accompanied by reductions in body weight, 
which was not observed to the same extent with placebo. The 
prevalence of NAFLD is substantially increased in patients with 
obesity and excessive caloric intake contributes to triglyceride 
accumulation, which is exacerbated in NAFLD by impaired free 
fatty acid metabolism.29,36 Thus, a reduction in body weight may 
be expected to be associated with decreased liver steatosis, 
and weight reduction is an established treatment for NAFLD.37 
While visceral fat has been identified as a strong predictor of 
NAFLD,38 the relationship between subcutaneous adipose tis-
sue levels and NAFLD remains to be determined.39 Preclinical 
studies have suggested that the beneficial effect of GLP- 1RAs 
on hepatic lipotoxicity and inflammation may, at least in part, 
be independent of weight reduction.40,41 However, it is not 
yet known to what extent the effect of semaglutide on steato-
sis may result from a direct metabolic effect or is mediated via 
weight loss.
Although comparisons between subjects with or without type 2 
diabetes and with or without obesity are not robust due to the low 
numbers of non- diabetic subjects and subjects with BMI <30 kg/m2, 
subgroup analyses did not suggest any differences between these 
subgroups with regard to changes in liver stiffness or steatosis (data 
not shown).
Liver disease, including NAFLD, is associated with elevated lev-
els of liver enzyme levels.20,36 As such, reductions in enzyme lev-
els could suggest an improvement in liver function, although the 
clinical significance of a decrease in enzymes remains unknown. 
Consistent with our findings, decreased liver fat and adipose tis-
sue volume with reductions in ALT and AST levels were reported 
in a study of patients with type 2 diabetes not assessed for NAFLD 
who received dapagliflozin plus saxagliptin on a background of met-
formin, but these observations were not seen in patients treated 
with glimepiride plus metformin.42 Declines in ALT have been re-
ported in patients with treatment- related improvement or resolu-
tion of histological NASH18,43,44 and appear to be associated with 
weight reduction.21
Overall, our data align with other studies of GLP- 1RAs that have 
suggested a potential beneficial effect in NAFLD/NASH. In the re-
cent phase 2 trial, subcutaneous semaglutide resulted in more pa-
tients achieving NASH resolution without worsening of fibrosis 
compared with placebo (59% with semaglutide 0.4 mg/day vs 17% 
with placebo; P < .001).21 There was no significant difference in 
the proportion of patients with improvement in fibrosis between 
groups; however, fewer patients treated with semaglutide had fi-
brosis progression and improvements were observed in several bio-
markers of fibrosis. In another phase 2 study in subjects with obesity 
without diabetes, semaglutide was associated with improvements in 
ALT levels, body weight and NAFLD Fibrosis Score.20,45 Liraglutide 
has also been shown to significantly improve steatosis in patients 
with biopsy- proven NASH,18 and to reduce BMI, visceral fat, ami-
notransferase levels and glucose abnormalities in patients with 
biopsy- confirmed NASH and glucose intolerance.46 Furthermore, 
in a 6- month study of patients with uncontrolled type 2 diabetes, 
liraglutide was associated with a 31% reduction in liver fat content, 
measured by proton magnetic resonance spectroscopy.19 The safety 
profile was consistent with semaglutide trials in other disease ar-
eas22- 25 and with the GLP- 1 class.
Although semaglutide did not result in a significant improvement 
in the primary endpoint of liver stiffness compared with placebo, 
there was a significant reduction in liver steatosis. This, together 
with other findings, including weight loss, improved glycaemic con-
trol and reductions in liver enzymes may suggest that treatment 
with semaglutide has a potentially beneficial impact on disease ac-
tivity and metabolic profile in a population with NAFLD.
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